Figure 2.

WBs detect lower or no change of serum MG53 levels in db/db mice or patients with diabetes compared with control subjects. A: 0.05–0.20 ng rhMG53 dissolved in mg53^−/− serum was used to establish the linear range for WB with the mAb-MG53, and 1 or 2 µL serum derived from the C57BL/6 mice was loaded onto the same gel. The WB was representative of 15 other samples. B: 1 µL sera derived from WT (lanes 1–5) and db/db littermates (lanes 6–10) (purchased from The Jackson Laboratory [age 14 weeks]) was probed with mAb-MG53. Loading control represents staining of albumin. C: Normalized WB intensities of MG53 in sera were plotted for individual animals. MG53 levels in db/db serum were significantly lower than those in WT serum (**P < 0.001). D: 1 µL sera derived from human individuals without diabetes and with diabetes was probed with mAb-MG53. E: Scatter plot of MG53 levels in sera of humans without diabetes and with diabetes. No significant differences were observed between the two groups (P = 0.113). F: Plot of serum MG53 level vs. fasting blood glucose in both samples of humans without diabetes and samples of humans with diabetes revealed no correlation (R² = 0.048).